Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Ribonuclease A (RNase A) is an endoribonuclease enzyme that catalyzes the hydrolysis of phosphodiester bonds in RNA molecules by cleaving at the 3' phosphate of pyrimidine nucleotides[3]. It is a single-chain polypeptide containing 4 disulfide bridges and exhibits highest activity with single-stranded RNA[3]. The enzyme is derived from bovine pancreas and is widely used in molecular biology applications including plasmid purification, genomic DNA isolation, removal of RNA from DNA samples, and diagnostic assay manufacturing[2]. RNase A has shown potential therapeutic applications including **antitumor activity** through its cytotoxic effects on cancer cells, as well as antimicrobial properties including antibacterial, antiviral, and antifungal activities[1]. The enzyme can be inhibited by alkylation of His12 or His119 residues in its active site[3]. Human RNase A family members (RNase 1-8) participate in various physiological and pathological processes including infection control, immune regulation, neurological function, and cardiovascular protection[1].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on ribonuclease A.